[go: up one dir, main page]

WO2014060941A3 - Compounds and compositions of neuroprotective agents for treatment of neurological and neurodegenerative diseases - Google Patents

Compounds and compositions of neuroprotective agents for treatment of neurological and neurodegenerative diseases Download PDF

Info

Publication number
WO2014060941A3
WO2014060941A3 PCT/IB2013/059356 IB2013059356W WO2014060941A3 WO 2014060941 A3 WO2014060941 A3 WO 2014060941A3 IB 2013059356 W IB2013059356 W IB 2013059356W WO 2014060941 A3 WO2014060941 A3 WO 2014060941A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
compositions
disorders
neurological
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2013/059356
Other languages
French (fr)
Other versions
WO2014060941A2 (en
Inventor
Mahesh Kandula
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2014060941A2 publication Critical patent/WO2014060941A2/en
Publication of WO2014060941A3 publication Critical patent/WO2014060941A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Disclosed are compounds of formula I, their pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula (I) are also disclosed. Such compositions may be used for treating seizures, Huntington's disease, spasms, mental disease, mental disorders, schizophrenia, depression, stress, bipolar disorder, Alzheimer' s diseases, anxiety, ADHD, dementia, mood disorders, PTSD, sleeplessness, epilepsy, migraine, psychosis, OCD, autism, anxiety disorders, dementia, mania and cognitive disorders.
PCT/IB2013/059356 2012-10-17 2013-10-15 Compositions and methods of neuroprotective agents for the treatment of neurological and neurodegenerative diseases Ceased WO2014060941A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN4324/CHE/2012 2012-10-17
IN4324CH2012 2012-10-17

Publications (2)

Publication Number Publication Date
WO2014060941A2 WO2014060941A2 (en) 2014-04-24
WO2014060941A3 true WO2014060941A3 (en) 2014-07-10

Family

ID=50488841

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2013/059356 Ceased WO2014060941A2 (en) 2012-10-17 2013-10-15 Compositions and methods of neuroprotective agents for the treatment of neurological and neurodegenerative diseases

Country Status (1)

Country Link
WO (1) WO2014060941A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0136693A2 (en) * 1983-10-03 1985-04-10 Takeda Chemical Industries, Ltd. Production of cytidine derivatives
EP0188647A1 (en) * 1985-01-24 1986-07-30 NEOPHARMED S.p.A. Acylated derivatives of cytidine-diphosphate-choline, process for their preparation and their therapeutic use
WO2003072067A2 (en) * 2002-02-27 2003-09-04 Inspire Pharmaceuticals, Inc. Compositions and methods for treating epithelial and retinal tissue diseases
WO2003099840A1 (en) * 2002-05-24 2003-12-04 Isis Pharmaceuticals, Inc. Oligonucleotides having modified nucleoside units

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0136693A2 (en) * 1983-10-03 1985-04-10 Takeda Chemical Industries, Ltd. Production of cytidine derivatives
EP0188647A1 (en) * 1985-01-24 1986-07-30 NEOPHARMED S.p.A. Acylated derivatives of cytidine-diphosphate-choline, process for their preparation and their therapeutic use
WO2003072067A2 (en) * 2002-02-27 2003-09-04 Inspire Pharmaceuticals, Inc. Compositions and methods for treating epithelial and retinal tissue diseases
WO2003099840A1 (en) * 2002-05-24 2003-12-04 Isis Pharmaceuticals, Inc. Oligonucleotides having modified nucleoside units

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PONTONI, GABRIELE ET AL.: "Studies on enzyme-substrate interactions of cholinephosphotransferase from rat liver", BIOCHIMICA ET BIOPHYSICA ACTA, vol. 836, 11 September 1985 (1985-09-11), pages 222 - 232 *

Also Published As

Publication number Publication date
WO2014060941A2 (en) 2014-04-24

Similar Documents

Publication Publication Date Title
HK1217486A1 (en) Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use
WO2014087367A3 (en) Compositions and methods for the treatment of neurological diseases and its associated complications
PH12013501556A1 (en) IMIDAZO[5,1-f][1,2,4]TRIAZINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
MX366855B (en) Perfluorinated 5,6-dihydro-4h-1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use.
MY162413A (en) Novel heterocyclic derivatives and their use in the treatment of neurological disorders
MX2020013099A (en) Heteroaromatic compounds and their use as dopamine d1 ligands.
GEP20207149B (en) Allosteric modulators of nicotinic acetylcholine receptors
NZ605486A (en) Spiro-cyclic amine derivatives as s1p modulators
JO3569B1 (en) Cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use
PH12015500883A1 (en) Heteroaromatic compounds as dopamide d1 ligands
WO2014145887A8 (en) Benzimidazole derivatives and uses thereof
EP2416795A4 (en) Inhibitors of cognitive decline
PH12016501863A1 (en) Heteroaromatic compounds and their use as dopamine d1 ligands
PH12016501993A1 (en) Heteroaromatic compounds and their use as dopamine d1 ligands
IN2014DN09826A (en)
EA201690971A1 (en) PYRIDO [4,3-b] PYRAZIN-2-CARBOXAMIDES AS NEUROGENOUS MEANS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS
FI3541784T3 (en) Novel azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission
WO2014060941A3 (en) Compounds and compositions of neuroprotective agents for treatment of neurological and neurodegenerative diseases
WO2014057439A3 (en) Compositions and methods for treatment of neurological diseases and its associated complications
PH12014502780A1 (en) Azetidine and piperidine compounds useful as pde10 inhibitors
WO2014060925A3 (en) Compositions and methods for treatment of neurological and neurodegenerative diseases
JP2016520641A5 (en)
TH167610A (en) Derivatives 6-dipfluoromethyl-5, 6 dihydro-2H- [1,4] oxacin-3-amine.
CL2012000539A1 (en) Compounds derived from 3- (morpholin-4-yl) -propionic acid, s1p modulators; pharmaceutical composition; Useful in the treatment, relief or prevention of diseases of the central nervous system, such as neurodegenerative disorders, Alzheimer's diseases, major depression, autism, among others.

Legal Events

Date Code Title Description
122 Ep: pct application non-entry in european phase

Ref document number: 13847165

Country of ref document: EP

Kind code of ref document: A2